Study of TIL cell therapy for advanced liver, bile, or pancreas cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and have advanced liver/bile duct or pancreas cancer that has returned or spread.
- Your expected lifespan is more than 3 months, and your performance status is good enough (Karnofsky 60%+ or ECOG 0–2).
- You have tumor tissue that can be biopsied or removed, or fluid from the cancer where immune cells can be taken, plus at least one measurable tumor spot.
- Your recent blood and organ test results must meet thresholds (for example: adequate white blood cells/neutrophils/platelets, enough hemoglobin, and kidney/liver numbers not too high).
- You must be able to stop cancer treatments like chemo, targeted medicines, biologics, and radiation for at least 28 days before the tumor sample is taken.
- You must not need high-dose steroids (prednisone >15 mg/day or similar) or immune-suppressing treatment for autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
Hear when a new Treatment Side Effects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.